Showing results (311-320 of 496) with videos related to

Sort By:
Pageof 50
Journal of Cancer Policy|February 2, 2025
An empirical investigation into concerns over quality-adjusted life-years: A review of cost-effectiveness analyses in oncologyAdam J N Raymakers, Leah Z Rand, William B Feldman, et al.
JAMA Network Open|November 14, 2023
National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated ApprovalEdward R Scheffer Cliff, Rachel S Rome, Aaron S Kesselheim, et al.
Annals of Internal Medicine|August 7, 2023
Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary DiseaseWilliam B Feldman, Aaron S Kesselheim, Jerry Avorn, et al.
Plos One|July 6, 2023
The impact of electronic health record discontinuity on prediction modelingShreyas Kar, Lily G Bessette, Richard Wyss, et al.
The American Journal of Managed Care|April 30, 2014
Assessing the chiral switch: approval and use of single-enantiomer drugs, 2001 to 2011Walid F Gellad, Phillip Choi, Margaret Mizah, et al.
Health Affairs (Project Hope)|May 3, 2021
Diabetes Drugs: List Price Increases Were Not Always Reflected In Net Price; Impact Of Brand Competition UnclearAmeet Sarpatwari, Frazer A Tessema, Marie Zakarian, et al.
JAMA Health Forum|January 2, 2026
Changes in Medication Use During Medicaid Continuous Enrollment and UnwindingBenjamin N Rome, Jihye Han, Adrianna McIntyre, et al.
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|July 6, 2025
Impostor Syndrome: Fraudulent Participants in Qualitative Research Can Skew ResultsLeah Z Rand, Sarah McGraw, Junyi Wang, et al.
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|May 25, 2023
Transferable Exclusivity Vouchers and Incentives for Antimicrobial Development in the European UnionVictor L Van de Wiele, Adam Raymakers, Aaron S Kesselheim, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 12, 2021
Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010-2020Kevin Outterson, Ebiowei S F Orubu, John Rex, et al.
Pageof 50